NCT03175224: CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation

NCT03175224
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MET
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for dose escalation phase; Tumor must harbor a c-MET mutation (including deletions or fusions), amplification, or over overexpression
Exclusions: Untreated active symptomatic brain and/or central nervous system metastases requiring steroids- see trial for details
https://ClinicalTrials.gov/show/NCT03175224

Comments are closed.

Up ↑